Investment
Features
FeesSafety
Academy
More
Pluang+

Compare IDEXX Laboratories, Inc. (IDXX) vs Wells Fargo & Co (WFC) Price & Performance

IDEXX Laboratories, Inc.Trade
Wells Fargo & CoTrade

Price performance (Past 24H)

Key statistics

IDEXX Laboratories, Inc. vs Wells Fargo & Co — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Wells Fargo & Co trades at $88.93 (market cap $264.66B). The key difference: Wells Fargo & Co is far larger — about 5.7× IDEXX Laboratories, Inc.'s market cap, and Wells Fargo & Co pays a 2.29% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.

IDXXWFC
Market Cap
$46.22B$264.66B
Sector
HealthFinancials
52-Week High
$766.68$96.40
52-Week Low
$526.44$73.42
Enterprise Value
$47.12B
Dividend Yield
2.29%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.

The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.

Wells Fargo & Co

Wells Fargo (WFC) trades at $89.15, up 1.82% for the day, with a bullish technical signal from moving averages and a consensus analyst price target of $97.64. Recent earnings show a Q2 2026 beat but misses in prior quarters, while revenue and net income have grown steadily from 2022 to 2025. The company is expanding into digital services like tokenized deposits, announced in August 2026, to enhance corporate client offerings.

The stock presents a value opportunity with a P/E of 12.72 and strong profitability metrics, including a 25.97% net income margin. Risks include volatile cash flows, with operating cash flow negative in 2025, and competitive pressures in banking. Analyst sentiment is mixed but leans positive, with 45% buy ratings, supporting potential upside if execution improves.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX

About Wells Fargo & Co

Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.

Read more on WFC